Page 228 - ebook HCC

GENEV
EASL HCC SUMMITHCC SUMMIT
PROGRAMME AND ABSTRACTSAND ABSTRACTS
227
226 PROGRAMME GENEVA, SWITZERLANDA, SWITZERLAND EASL 227
226
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C19 Poster Board Number C20
LOW MIR-125B EXPRESSION IN HEPATOCELLULAR CARCINOMA IN CIRRHOSIS:
HEPATOCELLULAR CARCINOMA PREDICTS PROGNOSTIC FACTORS AND SURVIVAL
RECURRENCE AFTER LIVER TRANSPLANTATION

1
1
1
1
Claudio De Vito , Christophe Bourdeaux , Céline Delucinge-Vivier , Yosra Said , Zeineb Ben Ali , Kaouther El Jeri , Hanene Ben Temime ,
3
1
2
1
1
1
1
1
Christian Toso , Jan Lerut , Christine Sempoux , Gilles Mentha , Laura Rubbia-Brandt 1 Radhouane Dabbeche , Slim bouzaidi , Haifa Mekki , Leila Mouelhi , Fatma houissa ,
2
4
4
5
1
2
1
1 Clinical pathology, Geneva University Hospitals, , Geneva, Switzerland, Department of Sana Khedher , Mohammed Salem , Mohammed Kouni Chahed , Taoufik Najjar 1
2
Abdominal and Transplantation Surgery, Cliniques Universitaires Saint-Luc, Brussels, 1 Gastroenterology, Epidemiology, Charles Nicolle Hospital, Tunis, Tunisia
2
Belgium, University of Geneva, Division of Visceral and Transplantation Surgery,
3
4
5
Geneva University Hospitals , Geneva, Switzerland, Department of Pathology, Cliniques Corresponding author’s e-mail: yosrasaid10@yahoo.fr
Universitaires Saint-Luc, Brussels, Belgium
Corresponding author’s e-mail: claudio.devito@hcuge.ch
Aims: To evaluate prognostic factors and survival of hepatocellular cancer (HCC) in a
Tunisian population.
Introduction: Liver transplantation (LT) using Milan criteria (MC) provides the best option
of cure for cirrhotic patients with hepatocellular carcinoma (HCC). Despite accurate Methodology: We conducted a retrospective study including consecutive patients who
selection 10-15% of patients develop HCC recurrence after LT supporting the identification were hospitalized with HCC occurring in cirrhotic liver during a 10-years period.
of new markers to better select transplant candidates. MicroRNAs (miRNAs) are small
non-coding RNA that regulate gene expression at the post-transcriptional level and are
involved in many liver diseases including HCC. Results: A total of 101 cirrhotic patients with HCC were included; 64 male and 37 female.
Mean age was 65,4 years (31-88 years). Causative factors of liver cirrhosis included
Aims: The aim of this study is to identify a miRNA signature related to HCC recurrence hepatitis C and B in 62,2% and 25,7% of cases respectively . The Child Pugh class
after LT. was A, B and C in 30,7%, 50,5% and 18,8% of patients respectively. The diagnosis of
Methodology: From 1987 to 2010, 54 patients from two liver transplant centers (Geneva HCC was non invasive, relying on imaging and alphafetoprotein in most cases (95%).
and Brussels) were retrospectively included in this study. 27 patients who developed HCC
recurrence after LT and 27 matched patients for age, gender, number and size of tumors, Eighty four patients (83,2%)had an advanced HCC, with vascular or extra hepatic spread
MC, microvascular invasion, tumor differentiation and year of LT were selected. MiRNA in 58(57,5%)of them. Treatment was curative in 14 cases, based on surgical resection
from tumor were extracted from formalin fixed paraffine embedded tissue and miRNA in one case and percutaneous ablation in 13 cases. Six patients received transarterial
expression profile was performed using Nanostring technology and validated by qRT-PCR. chemoembolization as a palliative treatment. In 71 patients, only symptomatic treatment
CLINICAL POSTER ABSTRACTS among the criteria selection except for alpha-foeto-protein (AFP) (p<0.001). 53 miRNAs patients were surveillance, Child-Pugh classification A, low serum AFP level(<200 ng/ml), CLINICAL POSTER ABSTRACTS
was given. The median survival period was 11 months. The 3-year survival rate was
Results: Patients with recurrent and non recurrent HCC showed no statistically difference
59.1% Univariate analysis showed the factors associated with better survival for HCC
were statistically differentially expressed between the two groups among which 38 and 15
small tumour (<3 cm), no vascular invasion , curative treatment options, Okuda stage I,
were respectively up-regulated and down-regulated in recurrent HCC compared to non
CLIP score <2, BCLC stage A and B. In multivariate analysis, the factors associated with
recurrent HCC. Mir-125b, a known tumor suppressor miRNA in HCC, was identified to be
down-regulated in recurrent HCC and validated by qRT-PCR. Overall survival (OS) and
better survival were surveillance (p=0.003), Child-Pugh classification (p=0.01), and BCLC
recurrence free survival (RFS) using Kaplan-Meier analysis shown that low level of mir-
125b is significally associated with a shorter OS (p<0.001) and RFS (p<0.001). Moreover
no correlation was observed between mir-125b expression and AFP using regression stage (p = 0.035).
Conclusions: In our study surveillance, Child-Pugh classification and BCLC stage were
analysis (p=0.02, r =0.11).
2
determined to be important prognostic factors .HCC surveillance for cirrhotic patients
Conclusions: In this study we identified that low expression of mir-125b is associated with could detect HCC at early and curative stages.
HCC recurrence and shorter OS after LT. An assessment of mir-125b in HCC prior to LT
might provide an additional marker for a better selection of liver transplant candidates and
to reduce HCC recurrence.